LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD).

    Lotan, Itay / Romanow, Gabriela / Salky, Rebecca / Molazadeh, Negar / Vishnevetsky, Anastasia / Anderson, Monique / Bilodeau, Philippe Antoine / Cutter, Gary / Levy, Michael

    Annals of clinical and translational neurology

    2023  Volume 10, Issue 4, Page(s) 664–667

    Abstract: The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort ... ...

    Abstract The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort died, we estimated the upper limit of a 95% confidence interval of the crude mortality rate in the cohort to be 2.1%. These data suggest that mortality in MOGAD is lower than that reported in other neuroinflammatory diseases and comparable to the age-adjusted mortality rates of the general population in the United States. Additional studies are warranted to confirm this observation.
    MeSH term(s) Humans ; Myelin-Oligodendrocyte Glycoprotein/immunology ; Autoimmune Diseases/mortality ; Cohort Studies
    Chemical Substances Myelin-Oligodendrocyte Glycoprotein
    Language English
    Publishing date 2023-02-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2740696-9
    ISSN 2328-9503 ; 2328-9503
    ISSN (online) 2328-9503
    ISSN 2328-9503
    DOI 10.1002/acn3.51750
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Predictors of relapsing disease course following index event in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

    Molazadeh, Negar / Bilodeau, Philippe A / Salky, Rebecca / Bose, Gauruv / Lotan, Itay / Romanow, Gabriela / Anderson, Monique R / Matiello, Marcelo / Chitnis, Tanuja / Levy, Michael

    Journal of the neurological sciences

    2024  Volume 458, Page(s) 122909

    Abstract: Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune disease that can present as a monophasic or relapsing disease course. Here, we investigate the predictors of developing relapsing disease with a focus ... ...

    Abstract Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an autoimmune disease that can present as a monophasic or relapsing disease course. Here, we investigate the predictors of developing relapsing disease with a focus on the index event.
    Methods: MOGAD patients followed at Massachusetts General Hospital and Brigham and Women's Hospital were included. Data on demographic, clinical, and laboratory features were collected. Time-to-event survival analysis was performed using a Cox proportional hazards model. Univariate and multivariate regression analyses were performed.
    Results: We included 124 patients with a diagnosis of MOGAD of which 62.1% (n = 77) were female. The median (IQR) onset age and follow-up time were 31 (16, 45), and 4.08 (2.2, 7.9) years respectively. In total, 40.3% (n = 50) of patients remained monophasic and, 59.7% (n = 74) developed a relapsing course. The median (IQR) time between the index event and the second attack was 3(2, 13.7) months. Starting maintenance therapy following the index event was associated with decreased risk of relapsing disease (HR:0.26; 95%CI: 0.12, 0.54; P < 0.001). Maintenance therapy with intravenous immunoglobulin (HR:0.1; 95% CI:0.01, 0.78, P = 0.02), rituximab (HR: 0.21; 95%CI: 0.08, 0.55; P = 0.001), and mycophenolate mofetil (HR: 0.27; 95%CI: 0.09, 0.77; P = 0.01) was associated with a decreased risk of relapsing disease course. A polyphasic first attack (HR:2.4; 95%CI:1.31, 4.4; P = 0.004) and high CSF protein (HR:2.06; 95%CI: 1.01, 4.16; P = 0.04) were associated with a relapsing course.
    Conclusions: In MOGAD patients, starting maintenance therapy following the index event reduces the risk of relapsing disease regardless of age, sex, and onset phenotype, while polyphasic first attack, and elevated CSF protein predict relapsing disease course.
    MeSH term(s) Humans ; Female ; Male ; Myelin-Oligodendrocyte Glycoprotein ; Autoimmune Diseases ; Disease Progression ; Hospitals, General ; Immunoglobulins, Intravenous ; Autoantibodies ; Neuromyelitis Optica
    Chemical Substances Myelin-Oligodendrocyte Glycoprotein ; Immunoglobulins, Intravenous ; Autoantibodies
    Language English
    Publishing date 2024-01-30
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 80160-4
    ISSN 1878-5883 ; 0022-510X ; 0374-8642
    ISSN (online) 1878-5883
    ISSN 0022-510X ; 0374-8642
    DOI 10.1016/j.jns.2024.122909
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 308: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.

    Bilodeau, Philippe Antoine / Vishnevetsky, Anastasia / Molazadeh, Negar / Lotan, Itay / Anderson, Monique / Romanow, Gabriela / Salky, Rebecca / Healy, Brian C / Matiello, Marcelo / Chitnis, Tanuja / Levy, Michael

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2024  Volume 30, Issue 3, Page(s) 357–368

    Abstract: Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can cause optic neuritis, transverse myelitis, or acute disseminated encephalomyelitis (ADEM). Immunotherapy is often used for relapsing disease, but there is ... ...

    Abstract Background: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can cause optic neuritis, transverse myelitis, or acute disseminated encephalomyelitis (ADEM). Immunotherapy is often used for relapsing disease, but there is variability in treatment decisions.
    Objective: The objective was to determine the annualized relapse rates (ARRs) and incidence rate ratios (IRRs) compared to pre-treatment and relapse-freedom probabilities among patients receiving steroids, B-cell depletion (BCD), intravenous immunoglobulin (IVIG), and mycophenolate mofetil (MMF).
    Methods: Retrospective cohort study of patients with relapsing MOGAD treated at Mass General Brigham. ARRs and IRRs compared to pre-treatment, and relapse-freedom probability and odds ratio for relapse-freedom compared to prednisone were calculated.
    Results: A total of 88 patients met the inclusion criteria. The ARR on IVIG was 0.13 (95% confidence interval (CI) = 0.06-0.27) and the relapse-freedom probability after at least 6 months of therapy was 72%. The ARR on BCD was 0.51 (95% CI = 0.34-0.77), and the relapse-freedom probability was 33%. The ARR on MMF was 0.32 (95% CI = 0.19-0.53) and the relapse-freedom probability was 49%. In pediatric-onset disease, MMF had the lowest ARRs (0.15, 95% CI = 0.07-0.33).
    Conclusion: IVIG had the lowest ARRs and IRRs compared to pre-treatment and the highest relapse-freedom odds ratio compared to prednisone, while BCD had the lowest. In pediatric-onset MOGAD, MMF had the lowest ARRs.
    MeSH term(s) Humans ; Child ; Myelin-Oligodendrocyte Glycoprotein ; Immunoglobulins, Intravenous ; Retrospective Studies ; Prednisone ; Autoantibodies ; Neoplasm Recurrence, Local ; Mycophenolic Acid ; Immunotherapy ; Recurrence
    Chemical Substances Myelin-Oligodendrocyte Glycoprotein ; Immunoglobulins, Intravenous ; Prednisone (VB0R961HZT) ; Autoantibodies ; Mycophenolic Acid (HU9DX48N0T)
    Language English
    Publishing date 2024-02-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/13524585241226830
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4428: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Positive Predictive Value of MOG-IgG for Clinically Defined MOG-AD Within a Real-World Cohort.

    Manzano, Giovanna S / Salky, Rebecca / Mateen, Farrah J / Klawiter, Eric C / Chitnis, Tanuja / Levy, Michael / Matiello, Marcelo

    Frontiers in neurology

    2022  Volume 13, Page(s) 947630

    Abstract: Myelin oligodendrocyte glycoprotein antibody associated disease (MOG-AD) is a CNS demyelinating disease, typically presenting with optic neuritis, transverse myelitis, and/or ADEM-like syndromes. The positive predictive value (PPV) of MOG-IgG testing by ... ...

    Abstract Myelin oligodendrocyte glycoprotein antibody associated disease (MOG-AD) is a CNS demyelinating disease, typically presenting with optic neuritis, transverse myelitis, and/or ADEM-like syndromes. The positive predictive value (PPV) of MOG-IgG testing by live cell-based assay was reported to be 72% in a study performed at the Mayo Clinic using a cut-off of 1:20. PPV may vary depending upon the tested population, thus supporting further investigation of MOG-IgG testing at other centers. In this real-world institutional cohort study, we determined the PPV of serum MOG-IgG for clinically defined MOG-AD in our patient population. The Massachusetts General Brigham Research Patient Data Registry database was queried for patients with positive serum MOG-IgG detection, at least once, between January 1, 2017 and March 25, 2021. All were tested via the MOG-IgG1 fluorescence-activated cell sorting assay (Mayo Laboratories, Rochester, MN). MOG-IgG positive cases were reviewed for fulfillment of typical MOG-AD clinical features, determined by treating neurologists and study authors. Of 1,877 patients tested, 78 (4.2%) patients tested positive for MOG-IgG with titer ≥1:20, and of these, 67 had validated MOG-AD yielding a PPV of 85.9%. Using a ≥1:40 titer cutoff, 65 (3.5%) tested positive and PPV was 93.8%. Three MOG positive cases had a prototypical multiple sclerosis diagnosis (RRMS
    Language English
    Publishing date 2022-06-20
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2564214-5
    ISSN 1664-2295
    ISSN 1664-2295
    DOI 10.3389/fneur.2022.947630
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Multiple types of relapses in MOG antibody disease.

    Levy, Michael / Molazadeh, Negar / Bilodeau, Philippe Antoine / Vishnevetsky, Anastasia / Lotan, Itay / Salky, Rebecca / Anderson, Monique / Romanow, Gabriela / Lechner-Scott, Jeannette / Yeh, E Ann / Giovannoni, Gavin

    Multiple sclerosis and related disorders

    2023  Volume 72, Page(s) 104613

    MeSH term(s) Humans ; Myelin-Oligodendrocyte Glycoprotein ; Neuromyelitis Optica ; Recurrence ; Autoantibodies
    Chemical Substances Myelin-Oligodendrocyte Glycoprotein ; Autoantibodies
    Language English
    Publishing date 2023-03-12
    Publishing country Netherlands
    Document type Editorial
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2023.104613
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin.

    Sotirchos, Elias S / Vasileiou, Eleni S / Salky, Rebecca / Huda, Saif / Mariotto, Sara / Chen, John J / Levy, Michael

    Multiple sclerosis and related disorders

    2021  Volume 57, Page(s) 103462

    Abstract: Myelin oligodendrocyte glycoprotein (MOG)-antibody associated disease (MOGAD) is a distinct demyelinating disease of the central nervous system that often exhibits a relapsing course. Immune globulin (Ig) therapy has been proposed as maintenance therapy ... ...

    Abstract Myelin oligodendrocyte glycoprotein (MOG)-antibody associated disease (MOGAD) is a distinct demyelinating disease of the central nervous system that often exhibits a relapsing course. Immune globulin (Ig) therapy has been proposed as maintenance therapy to prevent relapses in MOGAD, but existing reports are limited to the use of intravenous Ig (IVIG). Subcutaneous Ig (SCIG) may exhibit several advantages over IVIG, including self-administration and less systemic adverse effects. Herein, we report six patients with MOGAD who were treated with subcutaneous Ig (SCIG) with good tolerability and without any relapses during follow-up. This supports the rationale for prospective randomized studies of SCIG in MOGAD.
    MeSH term(s) Autoantibodies ; Humans ; Immunoglobulin G ; Immunoglobulins, Intravenous ; Myelin-Oligodendrocyte Glycoprotein ; Prospective Studies
    Chemical Substances Autoantibodies ; Immunoglobulin G ; Immunoglobulins, Intravenous ; Myelin-Oligodendrocyte Glycoprotein
    Language English
    Publishing date 2021-12-13
    Publishing country Netherlands
    Document type Letter
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2021.103462
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Fatigue is a common symptom in myelin oligodendrocyte glycoprotein antibody disease.

    Ladakis, Dimitrios C / Gould, Jennifer / Khazen, Jenny M / Lefelar, Julia M / Tarpey, Scott / Bies, Charles J / Salky, Rebecca / Fitzgerald, Kathryn C / Bhargava, Pavan / Nourbakhsh, Bardia / Sotirchos, Elias S

    Multiple sclerosis journal - experimental, translational and clinical

    2022  Volume 8, Issue 4, Page(s) 20552173221131235

    Abstract: Background: Unlike multiple sclerosis and neuromyelitis optica, the burden of fatigue in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is unclear.: Objective: To compare fatigue levels between people with MOGAD and household ...

    Abstract Background: Unlike multiple sclerosis and neuromyelitis optica, the burden of fatigue in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is unclear.
    Objective: To compare fatigue levels between people with MOGAD and household controls (HC) and explore factors associated with fatigue severity.
    Methods: In a cross-sectional survey, data were collected from people with MOGAD and HC by utilizing an online questionnaire. Data elements included demographics, sleep quality measures, comorbidities, MOGAD characteristics, and fatigue severity measured by the Modified Fatigue Impact Scale (MFIS). We compared fatigue severity between MOGAD participants and HC and assessed the associations between demographic and disease characteristics and fatigue severity.
    Results: There were 180/283 MOGAD and 61/126 HC respondents. Compared to HC, people with MOGAD reported more severe fatigue, as measured by the MFIS total score (49.3 vs. 36.5;
    Conclusions: Fatigue is common in people with MOGAD, and a history of bilateral optic neuritis, comorbid conditions, and ongoing disease activity appear to contribute to fatigue severity.
    Language English
    Publishing date 2022-11-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2841884-0
    ISSN 2055-2173 ; 2055-2173
    ISSN (online) 2055-2173
    ISSN 2055-2173
    DOI 10.1177/20552173221131235
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease.

    Lotan, Itay / Chen, John J / Hacohen, Yael / Abdel-Mannan, Omar / Mariotto, Sara / Huda, Saif / Gibbons, Emily / Wilf-Yarkoni, Adi / Hellmann, Mark A / Stiebel-Kalish, Hadas / Pittock, Sean J / Flanagan, Eoin P / Molazadeh, Negar / Anderson, Monique / Salky, Rebecca / Romanow, Gabriela / Schindler, Patrick / Duchow, Ankelien Solveig / Paul, Friedemann /
    Levy, Michael

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2023  Volume 29, Issue 9, Page(s) 1080–1089

    Abstract: Background: The potential therapeutic benefit of intravenous immunoglobulins (IVIGs) for acute attacks of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is unknown.: Objective: The objective was to describe the outcomes of IVIG ... ...

    Abstract Background: The potential therapeutic benefit of intravenous immunoglobulins (IVIGs) for acute attacks of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is unknown.
    Objective: The objective was to describe the outcomes of IVIG treatment for acute MOGAD attacks.
    Methods: A retrospective observational study involving seven tertiary neuroimmunology centers. Data collection included patients' demographics, Expanded Disability Status Scale (EDSS), and visual acuity (VA) before the attack, at the nadir of the attack before IVIG treatment, and at follow-up visits ⩾3 months after treatment.
    Results: Thirty-nine patients were included, of which 21 (53.8%) were female. The median age was 23 years (range 5-74 years), and the median disease duration was 4 months (range 0-93 months). The most common type of attack treated with IVIG was isolated optic neuritis (ON) (unilateral
    Conclusion: IVIG may be an effective treatment option for acute MOGAD attacks. Further prospective studies are warranted to validate our results.
    MeSH term(s) Female ; Male ; Humans ; Immunoglobulins, Intravenous/therapeutic use ; Myelin-Oligodendrocyte Glycoprotein ; Autoantibodies ; Myelitis, Transverse ; Encephalomyelitis, Acute Disseminated/drug therapy ; Retrospective Studies ; Neuromyelitis Optica
    Chemical Substances Immunoglobulins, Intravenous ; Myelin-Oligodendrocyte Glycoprotein ; Autoantibodies
    Language English
    Publishing date 2023-07-10
    Publishing country England
    Document type Observational Study ; Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/13524585231184738
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4428: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top